Eli Lilly and AdvanCell Announce Strategic Collaboration to Advance Alpha Therapies for Cancer Treatment

U.S. pharmaceutical giantEli LillyEli Lilly and Company (LLY.US) recently announced a collaboration agreement with Australian biotechnology company AdvanCell to jointly develop alpha therapies for cancer treatment.

AdvanCell is a biotechnology company focused on radiopharmaceutical therapy, with its core technology being the alpha isotope generator, which addresses the biggest challenge in targeted alpha therapy: the stable and scalable supply of isotopes. This breakthrough technology has the potential to provide more reliable treatment options for cancer patients.

According to the agreement, AdvanCell will provide its Pb-212 (lead-212) production technology and radiopharmaceutical development infrastructure, integrating with Eli Lilly and Company's pipeline of investigational drugs to advance the development of a series of targeted alpha therapies. Pb-212 is a radioactive isotope that can be used for precise targeting of cancer cells, reducing damage to healthy tissues and enhancing efficacy while minimizing side effects.

Currently, the most advanced candidate drug in AdvanCell's R&D pipeline, ADVC001, has entered Phase I/II clinical trials, primarily for the treatment of prostate cancer. This collaboration is expected to accelerate the development of this therapy, bringing new hope for cancer patients.

Editor: Guo Mingyu